CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP MOUTHWASH

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

CHLORHEXIDINE GLUCONATE

Verfügbar ab:

SAGE PRODUCTS LLC

ATC-Code:

A01AB03

INN (Internationale Bezeichnung):

CHLORHEXIDINE

Dosierung:

0.12%

Darreichungsform:

MOUTHWASH

Zusammensetzung:

CHLORHEXIDINE GLUCONATE 0.12%

Verabreichungsweg:

BUCCAL

Einheiten im Paket:

15ML/473ML

Verschreibungstyp:

Prescription

Therapiebereich:

MISCELLANEOUS ANTI-INFECTIVES

Produktbesonderheiten:

Active ingredient group (AIG) number: 0107629007; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2022-04-22

Fachinformation

_ _
_ _
_Page 1 of 19_
PRODUCT MONOGRAPH
CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP
Chlorhexidine Gluconate 0.12% Oral Rinse
Liquid, 0.12% Chlorhexidine Gluconate
Antigingivital Oral Rinse
Sage Product LLC
3909 Three Oaks Road
Cary, IL 60013
USA
Date of Preparation:
February 17, 2015
Submission Control No: 180308
_ _
_ _
_Page 2 of 19_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................6
OVERDOSAGE
..................................................................................................................7
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
SPECIAL HANDLING INSTRUCTIONS
.........................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
...............................................................................11
PHARMACEUTICAL INFORMATION
..........................................................................11
CLINICAL TRIALS
..........................................................................................................12
DETAILED PHARMACOLOGY
.........................